So she has spent a lot of time with the organization understanding the strategic priorities, work streams and stuff. And so we feel very fortunate to have her leading our aesthetic efforts, and she’s doing a great job and has really been intimately involved with a lot of the streamlining efforts that we have made. And we think her background is uniquely suited to help us get to where we need to go on the aesthetic side. On the Therapeutic side, as we announced, we added the additional responsibility to Dr. David Hollander, our Chief Medical Officer, Global Franchise Head for the Therapeutics group. And I think given his background and experience being an M.D., particularly within the neurology community, we think that not only does he have the gravitas from a leadership and skill set, but we think being an M.D., and with our targeted launch, he’s going to really help ensure that we position this thing the right way, that we’re understanding the subtleties around how physicians are using it, and how best to position ourselves for the future growth.
And so David’s always been close to the program, but more on the medical side, and now in sort of the leadership side, we feel really good to have him in that role. As we said, it’s going to be a targeted launch. We’ll start with about 40 commercial folks across sales, reimbursement, market access, and medical affairs. And we’ve got a lot of the leaders already in place in that functional area that David’s already had a chance to work with. And so we feel that we’ve got the right infrastructure in place to execute on our plan.
Operator: Our next question today is from the line of Serge Belanger of Needham & Company.
Serge Belanger: A couple of questions on the upcoming DAXI launch in cervical dystonia. It looks like you’ve made some significant — securing the coverage, at least on the commercial side. Maybe just talk about the nature of that coverage, how it compares to the other neurotoxins, whether it will impede usage outside of cervical dystonia? And maybe just cover also your plans and time lines for Medicare coverage?
Mark Foley: Sure. So on the coverage side of it, if you look it’s about 60% of the overall CD lives. We’re over 50% already. And within that, about almost 2/3 of that coverage is going to be first line therapy. So we feel like at least in CD coming into the market, we’ve got a really strong position within the commercial payer community in terms of our ability to compete effectively and not have any step edits or limits. Within the commercial category, maybe 14% will have a step edit. And so we’ll continue to work to knock that down with additional payer data. Right now, we don’t have a lot of payer data to go back to those. And so we really like sort of the response that we’ve gotten in the adoption, and we’ve made great progress with a lot of the top groups there.
On the Medicare side, we already have 100% coverage. On the Medicare side, that’s about 20% of the market. And then same thing on the Federal side, and we have a little bit more work to do on the Medicaid side of it. But all in all, the team has made tremendous progress in terms of the overall coverage side of it. With respect to spontaneous use, obviously, we can only promote for CD, but there are a number of the coverage policies which are agnostic to the toxin. So you have some that will look at toxins as sort of a general category, and if you get toxin coverage within that payer network, then they leave it up to the physicians to ultimately use the product in a way that they see fit. Others will allow for coverage of other indications with additional data.
It doesn’t need to be indication data, it can be additional data. And then some are very rigid in terms of only covering those indications where you have an FDA approval. So we feel like we’re really well positioned in cervical dystonia, and we’re also encouraged by some of the payers that are looking at this as sort of a generic category where the approval of DAXXIFY will allow the payers to ultimately manage the category the way that they think makes the most sense, along with the clinicians.
Operator: [Operator Instructions] And our next question is from the line of Uy Ear of Mizuho.
Charles Wang: This is Charles on for Uy. I guess, I had a question about the expanded label for the [RHA3] launch. And just do you think that’s going to be a modest contribution to the sales in this year?
Mark Foley: Sure. Well, I mean, the nice thing about the indication is you can teach, train, market, promote to it. And given that lips is the most commonly performed HA filler procedure, having that ability to directly target, promote, teach, train and go after it definitely helps. And so it’s another thing to talk about, and I think it speaks to the ongoing innovation pipeline that Teoxane is bringing forward in the RHA line. And so it’s just yet another thing for us to get in front of customers to talk about. It allows us to get behind it from a promotional standpoint. So listen, I don’t think it’s the kind of thing that’s going to create step function difference in the growth, but it does all help and contribute to the ability for us to have something else to talk to customers about, and to get trial perhaps in accounts that maybe have not yet leaned in.
And it fits also really well with Redensity which is used for perioral lines. And so it’s a nice combination of using RHA3 for a lip fullness and then using RHA Redensity for the areas kind of around the lips. And so it just, again, gives us yet more to talk about with our customers more reason to engage and more reason to get trial.
Operator: Thank you. And this will conclude the Revance Therapeutics Fourth Quarter and Full Year 2023 Financial Results and Corporate Update Conference Call. Thank you all for joining. You may now disconnect your lines.
